Performance analysis of Radiopharm Theranostics (RADX)
Annual Return
Since Dec 5, 2024, RADX has had an average annual return of -58.16%, underperforming the benchmark SPY, which returned +15.21% annual.
| 2026 | 2025 | 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.81% | +16.25% | -74.59% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.25% | -1.19% | -13.81% | -0.70% | +7.24% | -8.53% | +2.40% | -17.81% | |||||
| 2025 | +3.35% | +7.77% | -3.82% | -18.70% | +18.93% | -0.23% | +1.29% | +16.80% | +0.55% | -4.71% | -13.30% | +14.45% | +16.25% |
| 2024 | -74.59% | -74.59% |
Drawdown analysis of Radiopharm Theranostics (RADX)
The maximum drawdown for the RADX was -79.68%, occurring on Jul 7, 2025. This drawdown has not yet recovered.
The current RADX drawdown is -77.30%.
Since Dec 5, 2024 RADX has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -79.68% | Dec 6, 2024 | 142 | Jul 7, 2025 | Ongoing | Ongoing | Ongoing |